AbCellera and Recursion Pharmaceuticals: two AI-drug stocks, two different stories
AbCellera (ABCL) and Recursion (RXRX) are AI-driven biotechs with divergent profiles. ABCL's stock surged 169.7% in a year but is overvalued by 44.4% according to fair value estimates, while RXRX fell 28.2% and is near fair value. ABCL's revenue is volatile, and RXRX's losses are accelerating. Analysts see 17.8% upside for ABCL and 97.7% for RXRX. Technical indicators suggest ABCL is overbought, while RXRX is range-bound.
How this was made
The 30-second read
Why it matters
Provides a qualitative assessment of each stock's relative attractiveness but no new primary data.
Market read
Useful for traders considering a long RXRX / short ABCL pair, but no fresh catalyst disclosed.
What to watch
Potential impact of broader AI hype and macro risk appetite on both stocks.
Background
The article compares two clinical‑stage AI‑drug companies, providing valuation metrics and a pairs‑trade thesis.
Ticker impact
AbCellera is the article's subject, with a binary Phase 2 catalyst and overvalued fair value discussed.
Short-term downside risk if Phase 2 data disappoints; limited upside.
Article highlights overvaluation and technical exhaustion, suggesting a bearish bias.
Recursion is the article's subject, presented as a better-valued AI‑biotech with upside potential.
Potential upside if market re‑prices valuation and revenue growth continues.
The piece argues RXRX is undervalued relative to peers, implying a buying opportunity.
Market effects
Highlights valuation divergence within AI‑biotech sector.
U.S. biotech investors may re‑evaluate exposure to AI‑driven drug companies.
Limited to investors tracking AI‑biotech thematic trades.
Counterpoint
AbCellera could rally sharply if Phase 2 data exceed expectations, despite current overvaluation.
Key entities
- companyAbCellera
Clinical‑stage biotech focused on AI‑enabled antibody discovery.
- companyRecursion Pharmaceuticals
AI‑driven drug discovery firm with a focus on phenotypic screening.
